Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer

Abstract

This invention relates to LY6G6F, VSIG10, TMEM25 and LSR proteins, which are suitable targets for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders, and drug development. This invention further relates to soluble LY6G6F, VSIG10, TMEM25 and LSR molecules, extracellular domains of LY6G6F, VSIG10, TMEM25 and LSR and conjugates, which are suitable drugs for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders. This invention further relates to antibodies and antigen binding fragments and conjugates containing same, and/or alternative scaffolds, specific for LY6G6F, VSIG10, TMEM25 or LSR molecules, which are suitable drugs for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders.

What is claimed is: 
     
         1 . A method for treating a subject in need thereof for cancer, the method comprising administering to the subject a monoclonal or polyclonal antibody or an antigen binding fragment thereof comprising an antigen binding site that binds specifically to an isolated polypeptide consisting essentially of an amino acid sequence as set forth in any one of SEQ ID NOs: 3, 4 or 60. 
     
     
         2 . The method of  claim 1 , wherein the treatment is combined with another moiety or therapy useful for treating cancer. 
     
     
         3 . The method of  claim 2 , wherein the therapy is radiation therapy, antibody therapy, chemotherapy, photodynamic therapy, adoptive T cell therapy, Treg depletion, surgery or combination therapy with conventional drugs. 
     
     
         4 . The method of  claim 2 , wherein the moiety is immunosuppressants, cytotoxic drugs, tumor vaccines, antibodies peptides, peptibodies, small molecules, chemotherapeutic agents or immunological modifiers. 
     
     
         5 . The method of  claim 4 , wherein the chemotherapeutic agent is cytotoxic or cytostatic agents. 
     
     
         6 . The method of  claim 5 , wherein the cytotoxic or cytostatic agent is paclitaxel, cisplatin, vinorelbine, docetaxel, gemcitabine, temozolomide, irinotecan, 5FU or carboplatin. 
     
     
         7 . The method of  claim 4 , wherein the immunological modifier is interferons and interleukins, immunostimulatory antibodies, growth hormones, cytokines, folic acid, vitamins, minerals, aromatase inhibitors, RNAi, Histone Deacetylase Inhibitors or proteasome inhibitors 
     
     
         8 . The method of  claim 1 , wherein the cancer is breast cancer, cervical cancer, ovary cancer, endometrial cancer, melanoma, bladder cancer, lung cancer, pancreatic cancer, colon cancer, prostate cancer, leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, B-cell lymphoma, Burkitt's lymphoma, multiple myeloma, Hodgkin's lymphoma, Non-Hodgkin's lymphoma, myeloid leukemia, acute myelogenous leukemia (AML), chronic myelogenous leukemia, thyroid cancer, thyroid follicular cancer, myelodysplastic syndrome (MDS), fibrosarcomas and rhabdomyosarcomas, uveal melanoma, teratocarcinoma, neuroblastoma, glioma, glioblastoma, keratoacanthomas, renal cancer, anaplastic large-cell lymphoma, esophageal squamous cells carcinoma, hepatocellular carcinoma, follicular dendritic cell carcinoma, intestinal cancer, muscle-invasive cancer, seminal vesicle tumor, epidermal carcinoma, spleen cancer, head and neck cancer, stomach cancer, liver cancer, bone cancer, brain cancer, cancer of the retina, biliary cancer, small bowel cancer, salivary gland cancer, cancer of uterus, cancer of testicles, cancer of connective tissue, myelodysplasia, Waldenstrom's macroglobinaemia, nasopharyngeal cancer, neuroendocrine cancer, mesothelioma, angiosarcoma, Kaposi's sarcoma, carcinoid, oesophagogastric, fallopian tube cancer, peritoneal cancer, papillary serous mullerian cancer, malignant ascites, gastrointestinal stromal tumor (GIST), or Von Hippel-Lindau syndrome (VHL), and wherein the cancer is non-metastatic, invasive or metastatic. 
     
     
         9 . The method of  claim 8 , wherein the cancer is any of melanoma, cancer of liver, renal, brain, breast, colon, lung, ovary, pancreas, prostate, stomach, multiple myeloma, Hodgkin's lymphoma, non Hodgkin's lymphoma, acute and chronic lymphoblastic leukemia and acute and chronic myeloid leukemia. 
     
     
         10 . A method of performing one or more of the following in a subject:
 a. increasing immune response,   b. upregulating pro-inflammatory cytokines;   c. inducing proliferation and/or expansion of T cells and/or NK cells;   d. promoting T cells and/or NK cell activity;   e. promoting antigenic specific T cell immunity;   f. promoting CD4+ and/or CD8+ T cell activation;   g. increasing interferon-.gamma. or TNF-.alpha. production by T-cells;   h. increasing IL-2 secretion;   i. alleviating T-cell suppression; and/or   j. increasing cytotoxic T cell activity,   
       comprising administering a monoclonal or polyclonal antibody or an antigen binding fragment thereof comprising an antigen binding site that binds specifically to an isolated polypeptide consisting essentially of an amino acid sequence as set forth in any one of SEQ ID NOs: 3, 4 and 60 to the subject.